Scientific Congresses in Metabolic Disorders

Selected Data Presentations

Select "Upcoming" to see a list of future scientific congresses in rare metabolic disorders. Select "Past" to review data and presentations from recent congresses. This is not intended to be a comprehensive resource of all congresses and congress materials across therapeutic and disease areas.

Congress materials may include information about investigational use(s) of compounds/products that are not approved for use by the U.S. Food and Drug Administration (FDA) and/or are inconsistent with the Prescribing Information. Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling is left to the discretion of the healthcare professional. Takeda makes no representations about whether investigational compounds or unapproved uses will be approved by the FDA.


Upcoming & Past Conferences

  • Upcoming

  • Past

Society for Inherited Metabolic Disorders (SIMD), 2024

April 14 - 17, 2024

Annual conference which aims to increase knowledge of and promote research in inborn errors of metabolism in humans and to stimulate interactions between clinicians and investigators in inborn errors of metabolism.

American College of Medical Genetics and Genomics (ACMG), 2024

March 12 - 16, 2024

Annual meeting to present both research and clinical topics that promote the science and the practice of clinical genetics and genomics.

WORLD Symposium, 2024

February 4 - 9, 2024

Annual research conference designed for basic, translational and clinical researchers, patient advocacy groups, clinicians, and all others who are interested in the latest research on lysosomal diseases.

Society for the Study of Inborn Errors of Metabolism (SSIEM), 2023

August 29 - September 1, 2023

Annual symposium providing the newest information in metabolism and genetics and offering the opportunity for networking, discussions, and exchange of experiences.

Vpriv® (velaglucerase alfa)

  • Treatment of infants and young children with Gaucher disease using velaglucerase alfa: a single-centre experience